search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
INFECTION PREVENTION


the technology fits into the hospi- tal’s future wireless and interoper- ability goals. “Next, the BD Alaris System and BD HealthSight solu- tions capture infusion data, for continuous quality improvement. Finally, the addition of the new BD HealthSight Clinical Advisor functionality aggregates disparate data from hospital systems to identify if a medication order is no longer clinically appropriate for a patient. The hosted soft- ware application enables robust medication-stewardship alerts, advanced analytics, and dashboards de- signed to improve patient outcomes. “To gain a holistic view of infusion- administration processes,” continued Utech, “the BD Knowledge Portal for Infusion Technologies is an intuitive, web- based reporting tool that quickly translates BD Alaris System data into actionable intelligence that helps drive clinical educa- tion, drug-library standardization, alarms management, and dose-error–reduction software compliance. Together with the BD HealthSight platform and its suite of advanced analytics solutions, action- able data can be accessed to help reduce variation and improve the practice. Device alarm data includes alarm types, counts, duration, care area, drug/fluid name, and the time associated with each infusion modality alarm, to help comply with The Joint Commission National Patient Safety Goals on Alarms Management.” ICU Medical’s aim also is to improve patient safety through a more effectively designed infusion system. Matthew Hutchings, Vice President Global Market- ing & Innovation, Infusion Systems, de- scribed ICU Medical’s Plum 360 infusion system as having a unique, proprietary, cassette delivery system that provides a direct connection for the secondary line, which helps to eliminate secondary set- up errors shown to occur in 48 percent of secondary infusions. “This includes elimi- nating the need for bag-height differential and alerting clinicians when a secondary clamp is left closed,” said Hutchings. Hutchings referred to the Institute for


Safe Medication Practices’ (ISMP) draft guidelines, which include a recom men- da tion (item 1.7) for secondary delivery.3 “Use an automated secondary IV infusion management system that is not dependent on head height differential and has the ability to assure secondary flow.” Hutch- ings averred, “The Plum 360 infusion system meets this guideline for secondary delivery with the cassette-based delivery system.”


ICU Medical’s Plum 360 infusion system


Talking about the high cost of sepsis and


the role of an infusion system in its preven- tion, Hutchings noted that sepsis is the leading cause of death in hospitals and is the most expensive condition to treat, with U.S. total annual hospital costs of more than $24 billion.4


He also referred to a white


paper from Premier Inc, “Creating a Culture of Optimal Care Delivery,” published in October 2018, that stated the average cost per case for hospital-associated sepsis has jumped more than 20 percent since 2015, in excess of $70,000. “Research shows that poor sepsis out- comes occur when diagnosis and treat- ment are delayed,”5


said Hutchings. “The


‘sepsis bundle’ is the cornerstone of sepsis quality improvement. Two key elements of the bundle are the administration of broad-spectrum IV antibiotics and fluid resuscitation with an IV crystalloid fluid. The bundle should be started immediately upon diagnosis. The Plum 360 smart pump has the unique ability to guarantee second- ary delivery, ensuring a secondary delivery of antibiotic is not missed.” Hutchings cited a study by Prusch et


al6


in support of IV interoperability as a patient-safety measure. The study aimed to develop, implement, and evaluate an IV interoperability program to improve medi- cation safety at the bedside. The study con- cluded, “By integrating two stand-alone technologies, IV interoperability was im- plemented to improve medication admin- istration. Medication errors were reduced, nursing workflow was simplified, and pharmacists became in- volved in checking infusion rates of IV medications.”6


Catheters and related devices Most hospital patients have one or more catheters in- serted during their stay. Patients, particularly the immunocompromised, are


24 January 2020 • HEALTHCARE PURCHASING NEWS • hpnonline.com


at risk of infection due to a catheter, be- cause it is invasive and provides ingress to pathogens. Doug Shook, Vice President of Mar- keting, Access Scientific, highlighted the attributes of POWERWAND mid- line and long peripheral intravenous catheters, made of ChronoFlex C with Bioguard technology in preventing potential infection. Infections become established on the catheter through the production of biofilm.7


He said they


are the only noncoated catheter shown to inhibit bacterial attachment, even during extreme exposures. It also is


FDA-cleared for thromboresistance. “These catheter characteristics help explain why only the POWERWAND has over 36,000 published catheter-days without a reported infection,” said Shook. Access Scientific feels confident that


users can achieve these results because of outcomes reported by current users. Fur- thermore, “If hospitals do not reach their targets, we provide meaningful reimburse- ment,” offered Shook. POWERWAND midline catheters en-


able clinicians to remove central-venous– access devices sooner, according to Shook, which can help reduce the rate of infec- tion. An outstanding example is found in a published scientific study focusing on Richmond Medical Center in Staten Island, which reduced CLABSI in one ventilator intensive-care unit by 100 percent using POWERWAND. The result was nearly $500k savings as compared with the previ- ous year.8 Access Scientific has such confidence in


their product that they offer a guaranteed re- duction in total central-line–associated (CL) bloodstream infections (BSI; CLABSIs) and central-line usage. “We guarantee, by using POWERWAND, hospitals can reduce their total CLABSIs by 10 percent and central line usage by 25 percent.” That may represent a substantial savings, as Shook noted that the cost of a CLABSI is estimated at $48,000 per incident.


POWERWAND by Access Scientific


Page 26

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56